Want to see COYA full AI Analyst Report?
COYA Stock Chart & Stats
$5.04
-$0.13(-2.97%)
At close: 4:00 PM EDT
$5.04
-$0.13(-2.97%)
Day’s Range― - ―
52-Week Range$3.71 - $7.55
Previous Close$4.25
Volume159.10K
Average Volume (3M)151.89K
Market Cap
$98.76M
Enterprise Value$94.04M
Total Cash (Recent Filing)$43.18M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Nov 11, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding23,457,850
10 Day Avg. Volume153,144
30 Day Avg. Volume151,888
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.26
Price to Sales (P/S)12.21
P/FCF Ratio-9.04
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue11.73
Enterprise Value/Gross Profit11.74
Enterprise Value/Ebitda-4.26
Forecast
1Y Price Target
$15.75Price Target Upside212.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.35
Revenue Forecast (FY)$1.07M
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of reported debt reduces borrowing-related financial risk and preserves flexibility for a clinical-stage company. A debt-free structure avoids interest obligations and refinancing pressure, giving Coya more capacity to direct available resources toward development programs and operations.
Strong Recent Revenue GrowthThe sharp increase in trailing revenue indicates meaningful recent commercial or collaboration-related top-line momentum. Although profitability remains weak, strong revenue growth and near-100% reported gross margin could provide a broader base for funding development if the trend persists.
ALS Program AdvancementCompleting planned ALSTARS enrollment is a material clinical-development milestone that moves COYA 302 toward topline data while the open-label extension can generate longer-term efficacy and safety evidence. These steps strengthen the program’s potential to define Coya’s lead asset.
Bears Say
Severe Operating LossesExtremely negative operating results show that Coya has not yet established a sustainable earnings model despite recent revenue growth. Continued large losses can limit internally funded investment, increase reliance on external capital, and make future performance highly dependent on successful development outcomes.
Persistent Cash BurnPersistent negative operating and free cash flow indicate that the business consumes cash rather than funding itself. Unless burn moderates, Coya will continue to require careful runway management or additional financing, creating dilution or funding risk while clinical programs remain in development.
FTD Trial DeferralDeferring the FTD trial slows diversification of Coya’s clinical pipeline and concentrates near-term execution around the ALS program. A narrower active development focus may delay additional clinical proof points and leave future progress more dependent on the ALSTARS data readout.
Coya Therapeutics, Inc. News
COYA FAQ
What was Coya Therapeutics, Inc.’s price range in the past 12 months?
Coya Therapeutics, Inc. lowest stock price was $3.71 and its highest was $7.55 in the past 12 months.
What is Coya Therapeutics, Inc.’s market cap?
Coya Therapeutics, Inc.’s market cap is $98.76M.
When is Coya Therapeutics, Inc.’s upcoming earnings report date?
Coya Therapeutics, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 20 days.
How were Coya Therapeutics, Inc.’s earnings last quarter?
Coya Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.346 by $0.066.
Is Coya Therapeutics, Inc. overvalued?
According to Wall Street analysts Coya Therapeutics, Inc.’s price is currently Undervalued.
Does Coya Therapeutics, Inc. pay dividends?
Coya Therapeutics, Inc. does not currently pay dividends.
What is Coya Therapeutics, Inc.’s EPS estimate?
Coya Therapeutics, Inc.’s EPS estimate is -0.34.
How many shares outstanding does Coya Therapeutics, Inc. have?
Coya Therapeutics, Inc. has 23,457,850 shares outstanding.
What happened to Coya Therapeutics, Inc.’s price movement after its last earnings report?
Coya Therapeutics, Inc. reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.346. Following the earnings report the stock price went up 3.448%.
Which hedge fund is a major shareholder of Coya Therapeutics, Inc.?
Currently, no hedge funds are holding shares in COYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Coya Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.75 (212.50% Upside)
$15.75 (212.50% Upside)
Blogger Sentiment
Bullish
COYA Sentiment 100%
Sector Average 67%
Sector Average 67%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-36.01%
12-Months-Change
Fundamentals
Return on Equity
-53.32%
Trailing 12-Months
Asset Growth
41.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
COYA Stock 12 Month Forecast
Average Price Target
$15.75
▲(212.50% Upside)
Technical Analysis
Ownership Overview
4.42%
Insiders
4.45% Mutual Funds
21.50% Other Institutional Investors
65.18% Public Companies and
Individual Investors